Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study

Abstract

Background/aim

The importance of hepatocellular carcinoma (HCC) caused by obesity has been emphasized. Many studies have shown that weight fluctuations as well as high BMI are associated with various adverse outcomes. In this study, we investigated the relationship between weight fluctuation and HCC in general populations drawn from a nationwide population-based cohort.

Method

A population-based cohort study including 8,001,829 subjects participating in more than three health examinations within 5 years from the index year were followed until the end of 2017. The degree of weight fluctuation and incidence of HCC during the period were evaluated.

Results

When we classified groups according to baseline body mass index (BMI) level, the highest risk for HCC was observed in subjects with BMI of 30 or greater (adjusted hazard ratio [aHR] 1.40, 95% confidence interval [CI] 1.27–1.54). Also, increasing trends for the relationship between weight fluctuation and HCC were observed in multivariable Cox proportional analyses. The risk of HCC increased by 16% (aHR 1.16, 95% CI 1.12–1.20) for the highest quartile of weight fluctuation relative to the lowest quartile. These findings were consistent regardless of the baseline BMI or other metabolic factors. However, these effects of weight fluctuation on HCC were not observed in liver cirrhosis or viral hepatitis subgroups.

Conclusion

Weight fluctuation is an independent predictor of HCC. In the absence of liver cirrhosis or chronic hepatitis, the impact of weight fluctuation on HCC is further emphasized. These results suggest maintaining steady weight is recommended to reduce the risk of HCC.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Abbreviations

aHR:

Adjusted hazard ratio

ARV:

Average real variability

BMI:

Body mass index

CI:

Confidence interval

CKD:

Chronic kidney disease

CV:

Coefficient of variation

HDL:

High density lipoprotein

HR:

Hazard ratio

ICD-10:

International Classification of Disease, 10th revision

IL:

Interleukin

LDL:

Low density lipoprotein

NAFLD:

Nonalcoholic fatty liver disease

NHIS:

National Health Insurance Service

NHSP:

National Health Screening Program

Q:

Quartile

TNF:

Tumor necrosis factor

VIM:

Variability independent of the mean

References

  1. 1.

    Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–9.

    Article  Google Scholar 

  2. 2.

    Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis c virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(1090–9):e1.

    Google Scholar 

  3. 3.

    Henry ZH, Caldwell SH. Obesity and hepatocellular carcinoma: a complex relationship. Gastroenterology. 2015;149:18–20.

    Article  Google Scholar 

  4. 4.

    Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med. 2017;376:1332–40.

    Article  Google Scholar 

  5. 5.

    Yeboah P, Hsu FC, Bertoni AG, Yeboah J. Body mass index, change in weight, body weight variability and outcomes in Type 2 diabetes mellitus (from the ACCORD Trial). Am J Cardiol. 2019;123:576–81.

    Article  Google Scholar 

  6. 6.

    Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA. Weight change and risk of endometrial cancer. Int J Epidemiol. 2006;35:151–8.

    CAS  Article  Google Scholar 

  7. 7.

    Nagle CM, Marquart L, Bain CJ, O’Brien S, Lahmann PH, Quinn M, et al. Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer. 2013;49:2717–26.

    CAS  Article  Google Scholar 

  8. 8.

    Eng SM, Gammon MD, Terry MB, Kushi LH, Teitelbaum SL, Britton JA, et al. Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York. Am J Epidemiol. 2005;162:229–37.

    Article  Google Scholar 

  9. 9.

    Luo J, Margolis KL, Adami HO, Lopez AM, Lessin L, Ye W, et al. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women’s Health Initiative (United States). Am J Epidemiol. 2007;166:752–9.

    Article  Google Scholar 

  10. 10.

    Stevens VL, Jacobs EJ, Patel AV, Sun J, McCullough ML, Campbell PT, et al. Weight cycling and cancer incidence in a large prospective US cohort. Am J Epidemiol. 2015;182:394–404.

    Article  Google Scholar 

  11. 11.

    Nam GE, Park YG, Han K, Kim MK, Koh ES, Kim ES, et al. BMI, weight change, and dementia risk in patients with new-onset Type 2 diabetes: a nationwide cohort Study. Diabetes Care. 2019;42:1217–24.

    CAS  Article  Google Scholar 

  12. 12.

    Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabet Metab J. 2015;39:273–82.

    Article  Google Scholar 

  13. 13.

    Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.

    Article  Google Scholar 

  14. 14.

    Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.

    CAS  Article  Google Scholar 

  15. 15.

    Kikuya M, Ohkubo T, Metoki H, Asayama K, Hara A, Obara T, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52:1045–50.

    CAS  Article  Google Scholar 

  16. 16.

    Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70–85.

    Article  Google Scholar 

  17. 17.

    Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.

    Article  Google Scholar 

  18. 18.

    Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23:4742–54.

    Article  Google Scholar 

  19. 19.

    Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012;48:2137–45.

    Article  Google Scholar 

  20. 20.

    Schlesinger S, Aleksandrova K, Pischon T, Fedirko V, Jenab M, Trepo E, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645–57.

    CAS  Article  Google Scholar 

  21. 21.

    Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.

    CAS  Article  Google Scholar 

  22. 22.

    Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–80.

    CAS  Article  Google Scholar 

  23. 23.

    Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197–208.

    CAS  Article  Google Scholar 

  24. 24.

    Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int. 2015;35:2203–17.

    CAS  Article  Google Scholar 

  25. 25.

    Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52:1713–22.

    CAS  Article  Google Scholar 

  26. 26.

    Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, et al. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology. 2014;146(222–32):e35.

    Google Scholar 

  27. 27.

    Cereda E, Malavazos AE, Caccialanza R, Rondanelli M, Fatati G, Barichella M. Weight cycling is associated with body weight excess and abdominal fat accumulation: a cross-sectional study. Clin Nutr. 2011;30:718–23.

    Article  Google Scholar 

  28. 28.

    Dankel SN, Degerud EM, Borkowski K, Fjaere E, Midtbo LK, Haugen C, et al. Weight cycling promotes fat gain and altered clock gene expression in adipose tissue in C57BL/6J mice. Am J Physiol Endocrinol Metab. 2014;306:E210–24.

    CAS  Article  Google Scholar 

  29. 29.

    Li X, Jiang L, Yang M, Wu YW, Sun JZ. Impact of weight cycling on CTRP3 expression, adipose tissue inflammation and insulin sensitivity in C57BL/6J mice. Exp Ther Med. 2018;16:2052–9.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, Butt T, et al. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175(1289–306):e20.

    Google Scholar 

  31. 31.

    Kim S, Parks CG, DeRoo LA, Chen H, Taylor JA, Cawthon RM, et al. Obesity and weight gain in adulthood and telomere length. Cancer Epidemiol Biomarkers Prev. 2009;18:816–20.

    CAS  Article  Google Scholar 

  32. 32.

    Plentz RR, Caselitz M, Bleck JS, Gebel M, Flemming P, Kubicka S, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology. 2004;40:80–6.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the Soonchunhyang University Research Fund.

Funding

None.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Dong Wook Shin or Su Jong Yu.

Ethics declarations

Conflict of interest

All the authors have no conflict of interest.

Ethical approval

The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (E-1909-088-1065) and also conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki. The requirement for informed consent from individual subjects was waived, because we used de-identified secondary data.

Novelty and impact statements

This study demonstrated that weight fluctuation is an independent predictor of hepatocellular carcinoma in the nationwide population cohort. Therefore, maintaining steady weight is recommended to reduce the risk of hepatocellular carcinoma.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 85 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chang, Y., Yoo, JJ., Cho, E.J. et al. Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study. Hepatol Int (2021). https://doi.org/10.1007/s12072-021-10149-y

Download citation

Keywords

  • Hepatocellular carcinoma
  • Fluctuation
  • Weight
  • Obesity
  • Body mass index
  • Metabolic dysfunction
  • Inflammation
  • Telomere
  • Fatty liver
  • Diabetes